Materials, methods and devices for altering cell reactivity
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorMarvin J. Slepian
Life of this patent
Estimating the term…
Abstract
Methods, compositions, and devices to limit, modulate, insulate, and/or otherwise alter the effects of exogenous physical stimuli on cells are described herein. The cells may be removed from the body, preferably isolated, and treated ex vivo with the composition to limit the effects of physical stimuli on the cells and then returned to the patient. Alternatively, the cells may be treated in vivo. The compositions can be administered a variety of manners, such as systemically, locally or regionally.
Claims16
An ex vivo or in vivo method of treating human cells to modulate their reactivity to exogenous physical forces comprising administering to human cells subjected to exogenous physical forces, a composition comprising an effective amount of one or more agents selected from the group consisting of:
- (i) a lipid or lipid related compound, hormone, carbachol, atropine, inositol, DMSO, lidocaine, procaine, sex steroids, phenytoin, perylene, 9-(dicyanovinyl) julodinine, 1,6-diphenyl-1,3,5-hexatiene (DPH), TMA-DPH, DPH-PA, cis and trans-parinaric acid, wherein the hormone is selected from the group consisting of cortisol, estradiol, progesterone, medroxyprogesterone, insulin, glucagon, thyroid hormone, and aldosterone;
- (ii) sulindac sulfide, phenolic antioxidants, caffeic acid phenethyl ester (CAPE) FAK signaling and modulating agents, resveratrol, Rho kinase inhibitors, Y-27632, inhibitors or modulators of talin, paxilin, and viculin and submembrane mechnotransductive proteins;
- (iii) cytochlasins, concanavalin, vincristine, vinblastine, oryzalin, trifluralin, taxol, and taxetere;
- (iv) colchicine, colcemid, 9 bromonscapine (EM011), docetaxel, noscapinoids, and tau;
- or
- (v) hypo or hypertonic solutions, saline, lactated ringers, dextrose, sucrose, and mannitol, aqueporin receptors modulating agents, Hg Cl2, G-protein modulating agents, tolvaptan, convivaptan, and vaptans
- wherein the exogenous physical force provides a shear stress greater than 50 dynes/cm2, wherein the method further comprising using a ventricular assist device (VAD) to pump blood in a patient's body, wherein the exogenous physical force is a force provided by the VAD.
An ex vivo or in vivo method of treating cells to modulate their reactivity to exogenous physical forces comprising administering to cells subjected to exogenous physical forces, a composition comprising an effective amount of one or more agents selected from the group consisting of:
- (i) carbachol, atropine, inositol, DMSO, lidocaine, procaine, sex steroids, phenytoin, perylene, 9-(dicyanovinyl) julodinine, 1,6-diphenyl-1,3,5-hexatiene (DPH), TMA-DPH, DPH-PA, cis and trans-parinaric acid;
- (ii) sulindac sulfide, phenolic antioxidants, caffeic acid phenethyl ester (CAPE) FAK signaling and modulating agents, resveratrol, Rho kinase inhibitors, Y-27632, inhibitors or modulators of talin, paxilin, and viculin and submembrane mechnotransductive proteins;
- (iii) cytochlasins, concanavalin, vincristine, vinblastine, oryzalin, trifluralin, taxol, and taxetere;
- (iv) colchicine, colcemid, 9 bromonscapine (EM011), docetaxel, noscapinoids, and tau;
- and
- (v) hypo or hypertonic solutions, saline, lactated ringers, dextrose, sucrose, and mannitol, aqueporin receptors modulating agents, agonists or antagonists, Hg Cl2, G-protein modulating agents, vasopressin receptors modulators, tolvaptan, convivaptan, and vaptans
- wherein the exogenous physical force provides a shear stress of about 200 dynes/cm2 or greater.
An ex vivo or in vivo method of treating human cells to modulate their reactivity to exogenous physical forces comprising administering to human cells subjected to exogenous physical forces, a composition comprising an effective amount of one or more agents selected from the group consisting of:
- (i) a lipid or lipid related compound, carbachol, atropine, inositol, DMSO, lidocaine, procaine, sex steroids, phenytoin, perylene, 9-(dicyanovinyl) julodinine, 1,6-diphenyl-1,3,5-hexatiene (DPH), TMA-DPH, DPH-PA, cis and trans-parinaric acid;
- (ii) sulindac sulfide, phenolic antioxidants, caffeic acid phenethyl ester (CAPE) FAK signaling and modulating agents, resveratrol, Rho kinase inhibitors, Y-27632, inhibitors or modulators of talin, paxilin, viculin and submembrane mechnotransductive proteins;
- (iii) cytochlasins, concanavalin, vincristine, vinblastine, oryzalin, trifluralin, taxol, and taxetere;
- (iv) colchicine, colcemid, 9-bromonscapine (EM011), docetaxel, noscapinoids, and tau;
- (v) hypo or hypertonic solutions, saline, lactated ringers, dextrose, sucrose, and mannitol, aqueporin receptors modulating agents, agonists or antagonists, Hg Cl2, G-protein modulating agents, tolvaptan, convivaptan, and vaptans, and
- (v) a hormone selected from the group consisting of cortisol, estradiol, progesterone, medroxyprogesterone, insulin, glucagon, thyroid hormone, and aldosterone,
- wherein the exogenous physical force provides a shear stress of about 200 dynes/cm2 or greater, the method further comprising using a circulatory assist device to pump blood in a patient's body, wherein the circulatory assist device provides the exogenous physical force.
Dependencies are inferred from the claim text.